Drug Search Results
More Filters [+]

DF-9001

Alternative Names: DF-9001, DF 9001, DF9001
Latest Update: 2024-11-07
Latest Update Note: News Article

Product Description

DF-9001 is an immunotherapy agent targeting NK cells. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05597839)

Mechanisms of Action: EGFR Inhibitor,NK

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dragonfly Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DF-9001

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Head and Neck Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DF9001-001

P2

Recruiting

Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Renal Cell Carcinoma

2025-08-01

57%

Recent News Events